1Qing He Nie Yong Qian Cheng Yu Mei Xie Yong Xing Zhou Yi Zhan Cao The Center of Infectious Disease Diagnosis and Treatment of PLA,Tangdu Hospital,Forth Military Medical University,Xi’an 710038,Shaanxi Province,ChinaDr,Qing He Nie graduated from Qinghai Medical College as a doctor in 1983,got master degree at Beijing 302 Army Hospital in 1993,got doctor degree at the Third Military Medical University in 1998,engaged in postdoctoral research at the Fourth Military Medical University from 1998 to 2000,now an associate professor,specialized in clinical and experimental research of infectious diseases,had more than 90 papers published,coauthor of ten books,first author of one book..Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis[J].World Journal of Gastroenterology,2001,7(3):363-369. 被引量：73
5[1]Bismuth H,Farges O,Castaing D,Samuel D,Adam R,Johann M,Azoulay D,Feray C,Astarcioglu I,Saliba F.Evaluation of results of liver transplantation:experience based on a series of 1052 transplantations.Presse Med 1995; 24:1106-1114
6[2]Parrilla P,Sanchez-Bueno F,Figueras J,Jaurrieta E,Mir J,Margarit C,Lazaro J,Herrera L,Gomez-Fleitas M,Varo E,Vicente E,Robles R,Ramirez P.Analysis of the complications of the piggy-back technique in 1,112 liver transplants.Transplantation 1999; 67:1214-1217
7[3]Stange J,Mitzner S,Ramlow W,Gliesche T,Hickstein H,Schmidt R.A new procedure for the removal of protein bound drugs and toxins.ASAIO J 1993; 39:M621-625
8[4]Guo LM,Liu JY,Xu DZ,Li BS,Han H,Wang LH,Zhang WY,Lu LH,Guo X,Sun FX,Zhang HY,Liu XD,Zhang JP,Yao Y,He ZP,Wang MM.Application of Molecular Adsorbents Recirculating System to remove NO and cytokines in severe liver failure patients with multiple organ dysfunction syndrome.Liver Int 2003; 23 Suppl 3:16-20
9[5]Huang JF,He XS,Chen GH,Zhu XF,Lu MQ,Wang GD,Fu YY,Yang Y,Guan XD,Liver transplantation at the Sun YatSen University of Medical Sciences in China.Chin Med J 2002;115 (4):543-548
10[6]Alvares-da-Silva MR,Waechter FL,Francisconi CF,Barros E,Thome F,Traiber C,Fonseca DL,Zingani JM,Sampaio JA,Pinto RD,Pereira-Lima L.Risk factors for postoperative acute renal failure at a new orthotopic liver transplantation program.Transplant Proc 1999; 31:3050-3052
3Min-Guang Zhang, Xue-Jing Huang, Qiong Zhu, Jian Geng and An-Jun Zhang Department of Radiology, Shanghai Hospital of Traditional Chinese Medicine, Shanghai 200071 , China Department of Radiology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200021 , China.Relationship between CT grouping and complications of liver cirrhosis[J].Hepatobiliary & Pancreatic Diseases International,2006,5(2):219-223. 被引量：6
4Yi Pan, Zhao-Ming Wang, Ling-Jun Mou, Xiao-Dong Teng, Zhou-Jun Zheng and Li-Xiong Ying Hangzhou, ChinaDepartments of Pathology ,and General Surgery ,First Affilia- ted Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.Focal nodular hyperplasia of the liver: pathological analysis of 11 cases[J].Hepatobiliary & Pancreatic Diseases International,2004,3(2):199-203. 被引量：3
2Sabat R, Griitz G, Warszawska K, et al. Biology of interleukin-10.Cytokine Growth Factor Rev, 2010,21:331-344.
3#NAME?nard CL, Weaver CT. Diversity in the contribution of inter-leukin-10 to T-cell-mediated immune regulation. Immunol Rev,2008,226:219-233.
4Ryan JJ, Kashyap M, Bailey D, et al. Mast cell bomeostasis:a funda-mental aspect of allergic disease. Crit Rev Immunol, 2007,27:15-32.
5YeZ, Hang H, Ho S, et al. IL-10 has a distint immunoregulatory ef-fect on naive and active T cell subsets. J Interferon Cytokine Res,2007,27:1031-1038.
6Canivet C, B.hler T, Galvani S,et al. In vitro mitogen-stimulatedT -cell from hepatitis C virus 一positive liver transplantation, candi-dates, increases T-cell activation markers and T-cell proliferation.Transpl Immunol, 2008,19:112-119.
7Donath MY, Shoelson SE. Type 2 diabetes as an inflammato3" disease. Nat Rev hnmunol, 2011,11:98-107.
8Cruz M, Maldonado-Bernal C, Mondragon-Gonzalez R, et al. Glycine treatment decreases proinflammatory cytokines and increases interferon- gamma in patients with type 2 diabetes. J Endocrinol Invest, 2008,31 : 694-699.
9Van De Laar FA, Lucassen PL, Akkennans RP, et al. Alpha- glucosidase inhibitors for people with impaired glucose tolerance orimpaired fasting blood glucose. Cochrane Database Syst Rev, 2006: D5061.
10Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA, 2003,290 : 486- 494.
